GRT-C901 (Not yet branded)
Other Medications
Description
GRT-C901 is a personalized neoantigen cancer vaccine designed specifically for patients with metastatic colorectal cancer. This individualized immunotherapy is created by analyzing each patient's unique tumor mutations to identify neoantigens - abnormal proteins that can trigger an immune response against cancer cells. The vaccine is administered in combination with immune checkpoint blockade therapy and is specifically developed for patients with microsatellite stable (MSS) colorectal tumors.
Mechanism of Action
GRT-C901 works by training the patient's immune system to recognize and attack cancer cells displaying specific neoantigens unique to their tumor. The vaccine contains synthetic peptides or RNA sequences encoding these patient-specific neoantigens, which stimulate T-cell responses against the cancer. When combined with checkpoint inhibitors, this approach aims to overcome the typically poor immunotherapy response seen in MSS colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Subcutaneous |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.